Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA) is a clinical-stage pharmaceutical company developing oral small-molecule therapeutics for chemotherapy-induced peripheral neuropathy (CIPN), chronic inflammatory pain, and obesity. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. This Form 10-Q covers the quarterly and six-month periods ended June 30, 2026.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(2,358,686) | $(3,321,491) |
| Loss Per Share (Basic & Diluted) | $(0.06) | $(0.19) |
| Operating Expenses | $2,259,598 | $3,351,300 |
| Cash and Cash Equivalents (End of Period) | $3,609,442 | $730,475 |
| Short-Term Investments (Related Party) | $4,503,973 | $4,683,099 |
| Total Current Liabilities | $40,823 | $702,068 |
| Accumulated Deficit | $(41,938,892) | $(32,459,212) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $963,000 (29%) compared to the prior year period, driven primarily by a significant reduction in General and Administrative (G&A) expenses.
- G&A Expense Decline: G&A expenses dropped from $2.54 million to $1.03 million. This decrease is attributed to a $1.2 million reduction in stock-based compensation and lower payroll-related expenses.
- Increased R&D Spend: Research and Development expenses increased by $420,000 (52%) to $1.23 million. This reflects increased costs for pre-IND submission work for MIRA-55 and SKNY-1, and Phase 2a protocol advancement for Ketamir-2.
- Equity Method Loss: The company recognized a loss of $179,126 from its equity method investment in Telomir Pharmaceuticals, Inc. (Telo), a related party. No such loss was recorded in the prior year period.
- Liquidity Improvement: Cash balances increased from $730,475 to $3.61 million, despite a net cash outflow from operations of $2.4 million. This was supported by a prior period cash balance and the repayment of related party advances.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the 12 months following the issuance of these financial statements. The company has insufficient cash to fund operations for that period and expects to require significant additional external funding.
- Pipeline Progress:
- Ketamir-2: Phase 1 completed; targeting Phase 2a initiation in Q1 2027.
- MIRA-55 & SKNY-1: Advancing toward IND-enabling studies following toxicology studies.
- Nasdaq Compliance Risk: On July 27, 2026, the company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. The company has 180 days to regain compliance or face potential delisting, which could adversely affect capital raising efforts.
- Capital Requirements: The company anticipates needing additional capital to support development activities. Sources may include public/private equity, strategic alliances, or debt. Failure to secure funding could force the company to curtail operations.
Investor Verification Checklist
- Verify the company's specific plan and timeline for raising additional capital to address the "substantial doubt" regarding going concern status.
- Monitor the status of the Nasdaq minimum bid price compliance and any potential reverse stock split announcements.
- Review the terms of the related-party license agreements with MIRALOGX and the equity method investment in Telomir Pharmaceuticals (Telo) for potential conflicts or valuation risks.
- Confirm the timeline and regulatory milestones for the Phase 2a trial of Ketamir-2 and IND-enabling studies for MIRA-55 and SKNY-1.
- Assess the burn rate relative to the current cash balance of $3.6 million to estimate the runway before additional financing is critically required.